APA (7th ed.) Citation

Ganbaatar, B., Fukuda, D., Shinohara, M., Yagi, S., Kusunose, K., Yamada, H., . . . Sata, M. (2020). Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. European journal of pharmacology, 875, 173040. https://doi.org/10.1016/j.ejphar.2020.173040

Chicago Style (17th ed.) Citation

Ganbaatar, Byambasuren, Daiju Fukuda, Masakazu Shinohara, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Ken-ichi Hirata, and Masataka Sata. "Empagliflozin Ameliorates Endothelial Dysfunction and Suppresses Atherogenesis in Diabetic Apolipoprotein E-deficient Mice." European Journal of Pharmacology 875 (2020): 173040. https://doi.org/10.1016/j.ejphar.2020.173040.

MLA (9th ed.) Citation

Ganbaatar, Byambasuren, et al. "Empagliflozin Ameliorates Endothelial Dysfunction and Suppresses Atherogenesis in Diabetic Apolipoprotein E-deficient Mice." European Journal of Pharmacology, vol. 875, 2020, p. 173040, https://doi.org/10.1016/j.ejphar.2020.173040.